financetom
Business
financetom
/
Business
/
McDonald's sales miss estimates as customers cut back spending
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
McDonald's sales miss estimates as customers cut back spending
Apr 30, 2024 4:28 AM

April 30 (Reuters) - McDonald's fell short of

Wall Street estimates for first-quarter sales on Tuesday as

budget-conscious consumers cut back on restaurant meals and the

Middle East conflict weighed on the burger chain's international

sales.

Global comparable sales growth slid for the fourth straight

quarter to 1.9%, with the company saying consumers turned "more

discriminating with every dollar they spend". Analysts had

estimated a 2.35% rise, according to LSEG data.

The company has raised prices by roughly mid- to

high-single-digit percentage over the last year in response to a

rise in costs of eggs and other raw items.

Comparable sales in the company's International

Developmental Licensed Markets segment, which made up 10% of its

overall revenue in 2023, declined 0.2%, offsetting positive

trends from Japan, Latin America and Europe. Analysts had

expected a 0.98% rise for the unit.

Earlier in March, McDonald's CFO Ian Borden had warned of a

sequential fall in international sales in the first quarter,

pressured by the conflict in the Middle East and a sluggish

Chinese economy, its second-largest market after the United

States.

Higher competition for breakfast hour spending in the United

States has prompted the burger giant to lean on low-priced menu

choices including breakfast value bundles and a Dollar Menu

under the $4 price point.

First-quarter same-store sales grew 2.5% in the United

States, sharply lower than a 12.6% growth last year and slightly

below estimates of a 2.55% growth, signaling that cash-strapped

Americans remained picky about offers at fast-food chains amid

still-high inflation.

McDonald's posted quarterly adjusted per-share profit of

$2.70. Analysts had estimated $2.72, according to LSEG data.

Total operating costs and expenses increased 2% to $3.43

billion.

(Reporting by Savyata Mishra in Bengaluru; Editing by Saumyadeb

Chakrabarty)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Warburg Pincus sees uptick in private equity deals in 2025
Warburg Pincus sees uptick in private equity deals in 2025
Dec 10, 2024
NEW YORK (Reuters) - Warburg Pincus expects a material uptick in deals in the private equity industry in 2025 and 2026, driven by pressure to return capital to their investors, its chief executive officer Jeffrey Perlman said in an interview at the Reuters NEXT conference in New York on Tuesday. After couple of years with a low volume of deals, Perlman said...
Sector Update: Consumer
Sector Update: Consumer
Dec 10, 2024
01:31 PM EST, 12/10/2024 (MT Newswires) -- Consumer stocks were higher Tuesday afternoon, with the Consumer Staples Select Sector SPDR Fund (XLP) increasing 0.5% and the Consumer Discretionary Select Sector SPDR Fund (XLY) rising 0.9%. Redbook US same-store sales rose by 4.2% from a year earlier in the week ended Dec. 7, slower than a 7.4% year-over-year increase in the...
Matthews International Shares Up as Activist Investor Barington Capital Calls for Changes
Matthews International Shares Up as Activist Investor Barington Capital Calls for Changes
Dec 10, 2024
01:36 PM EST, 12/10/2024 (MT Newswires) -- Matthews International ( MATW ) shares were up 3% in recent trading Tuesday as the company acknowledged it received a nomination notice from activist investor Barington Capital Group. Barington Capital said earlier it had sent a letter to Matthews Chairman Alvaro Garcia-Tunon calling for the replacement of the company's long-time chief executive Joseph...
Chimerix Shares Soar Following Plans to Seek Accelerated Approval for Dordaviprone in Rare Brain Tumor
Chimerix Shares Soar Following Plans to Seek Accelerated Approval for Dordaviprone in Rare Brain Tumor
Dec 10, 2024
01:33 PM EST, 12/10/2024 (MT Newswires) -- Chimerix ( CMRX ) shares were up over 237% in recent trading Tuesday a day after the company said it plans to submit a new drug application with the US Food and Drug Administration seeking accelerated approval for dordaviprone. The application covers approval for dordaviprone as a treatment for recurrent H3 K27M-mutant diffuse...
Copyright 2023-2026 - www.financetom.com All Rights Reserved